Genitourinary Cancers | Specialty

Patricia Hofstra on Alternatives to Acquisition in Healthcare

March 25th 2015

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise

March 16th 2015

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

PD-1 Pathway Combos Lead the Way in RCC Immunotherapy

March 16th 2015

The prospects for combining anti–PD-1 pathway agents with other checkpoint blockade inhibitors or with agents that target angiogenesis are among the most promising immunotherapy approaches under development for patients with metastatic renal cell carcinoma.

Task Force PSA Recommendation Needs Updating, LUGPA President Says

March 16th 2015

A United States Preventive Services Task Force recommendation against the use of prostate specific antigen testing needs to be updated, said Gary Kirsh, MD, president of the Large Urology Group Practice Association.

Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer

March 14th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

Dr. Voss on Early Efficacy Signals in DART Study for Advanced Kidney Cancer

March 12th 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses early efficacy signals in the phase I/II DART study.

Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC

March 2nd 2015

Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).

Targeted-Chemo Combination Active In Sarcomatoid, High-Risk RCC

March 2nd 2015

A fourth of patients with sarcomatoid or poor-risk metastatic renal-cell carcinoma responded to treatment with the combination of sunitinib and gemcitabine.

Adding Anti-PD-L1 Antibody to Bevacizumab Induces Responses in mRCC

March 2nd 2015

An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.

Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC

February 26th 2015

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Dr. McKay on Statin Use in Patients With mRCC

February 26th 2015

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

Jim Feldman on the Importance of Social Networking for Urologists

February 24th 2015

Jim Feldman, chief innovative officer, Shift Happens, discusses change management for urologists and why it is important for them to have a social media presence.

Dr. Jonathan Henderson Discusses the Professional Need and Business Model for Men's Health Clinics

February 20th 2015

Jonathan Henderson, MD, urologist, Regional Urology, assistant director of clinical research, discusses how men's health clinics should be run by urologists.

Dana Jacoby on How a Group of Physicians Can Become a Successful Medical Group

February 19th 2015

Dana Jacoby, senior consultant, BSM Consulting, gives advice on how a group of physicians can build a strong, healthy culture when looking to form a successful medical organization.

Bob Asinof on Recruiting Physicians to Private Centers

February 18th 2015

Bob Asinof, chief executive officer of The Urology Center of Colorado, discusses the challenges of recruiting urologists to their center while competing with larger cancer centers and hospital systems.

Radium-223 for Treatment of Prostate Cancer

February 13th 2015

Antiandrogen Resistance With AR-V7 in CRPC

February 13th 2015

Enzalutamide Offers Second Option in Pre-Chemo CRPC

February 13th 2015

Pre-Chemotherapy Abiraterone Acetate in CRPC

February 13th 2015

Integrating CHAARTED Findings Into Prostate Cancer Care

February 13th 2015